![Marc Rogers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc Rogers
Nessuna posizione attualmente
Storia della carriera di Marc Rogers
Precedenti posizioni note di Marc Rogers
Società | Posizione | Inizio | Fine |
---|---|---|---|
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Direttore/Membro del Consiglio | - | 20/12/2023 |
Direttore Tecnico/Scientifico/R&S | - | - |
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Metrion Biosciences Ltd.
![]() Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Health Technology |
- Borsa valori
- Insiders
- Marc Rogers
- Esperienza